25773 A randomized, dose-escalating, double-blind study to evaluate abobotulinumtoxinA for the treatment of moderate-to-severe glabellar lines

2021 ◽  
Vol 85 (3) ◽  
pp. AB69
Author(s):  
John Joseph ◽  
Amir Moradi ◽  
Z. Paul Lorenc ◽  
Kyle Coleman ◽  
Glynis Ablon ◽  
...  
Keyword(s):  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Dose Escalating

Double-Blind Study of Antihistaminic Drugs

1973 ◽  
Vol 35 (5) ◽  
pp. 627-633
Author(s):  
Masayuki SHIMIZU ◽  
Yoshiko HIDAKA ◽  
Ryuhji TAKEUCHI
Keyword(s):  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Antihistaminic Drugs

OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

2017 ◽  
Vol 1 ◽  
pp. s82
Author(s):  
Steven Dayan ◽  
Patricia Ogilvie ◽  
Alexander Z Rivkin ◽  
Steven G Yoelin ◽  
Julie K Garcia ◽  
...  
Keyword(s):  
Blind Study ◽  
Double Blind Study ◽  
Phase 3 ◽  
Double Blind ◽  
Patient Reported

Abstract Not Available Disclosures: Study supported by Allergan.

Sign in / Sign up

Export Citation Format

Share Document